OsNF-YAs suppress JA signaling. by Xiaoxiang Tan (12542842)

Spray Flame Characterization of a Dual Injector for Compact Combustion Systems by Fabian Hampp (16892674)

Fits of mathematical model to the deuterium enrichment data of CD4⁺ T-cells. by Sara P. H. van den Berg (8703927)

Fits of mathematical model to the deuterium enrichment data of CD8⁺ T-cells. by Sara P. H. van den Berg (8703927)

RAINFALL REGIME ON FINE ROOT GROWTH IN A SEASONALLY DRY TROPICAL FOREST by EUNICE MAIA DE ANDRADE (4894216)

“…The fine root biomass in July 2015 was 7.7±5.0 Mg ha-1 and the length was 5.0±3.2 km m-2. …”

Table_1_Differential regulatory T cell signature after recovery from mild COVID-19.docx by Pedro Henrique de Sousa Palmeira (14758156)

“…Interestingly, Pool Spike CoV-2 elicited a decrease in Treg IL-17⁺ frequency in the Severe Recovered group. …”

DataSheet_1_Differential regulatory T cell signature after recovery from mild COVID-19.pdf by Pedro Henrique de Sousa Palmeira (14758156)

“…Interestingly, Pool Spike CoV-2 elicited a decrease in Treg IL-17⁺ frequency in the Severe Recovered group. …”

DEVELOPING A PORTABLE DEVICE TO CONTROL TEMPERATURE DURING SPECTROSCOPIC MEASUREMENTS by Daniel Aparecido Pires (14282016)

Parallel Spectral Acquisition with an Ion Cyclotron Resonance Cell Array by Sung-Gun Park (1430038)

“…As such, the time required for spectral acquisition of a given resolving power and mass accuracy decreases linearly with increasing fields. …”

Parallel Spectral Acquisition with an Ion Cyclotron Resonance Cell Array by Sung-Gun Park (1430038)

“…As such, the time required for spectral acquisition of a given resolving power and mass accuracy decreases linearly with increasing fields. …”

The TatA/Tat signal peptide contact does not require the TatBC components. by Johannes Taubert (702534)

“…Two <i>p</i>Bpa concentrations (0.1 mM and 0.01 mM) in the growth medium were used to analyze effects of lowered HiPIP concentration. <i>tatA</i>⁺<i>B</i>⁺<i>C</i>⁺: BW25113/pRK-<i>tatABC</i>/pEvol-pBpF /pEXH5<i>tac</i>-H6-A13<i>p</i>Bpa; <i>tatA</i>⁺<i>B</i>^-<i>C</i>^-: JBdBC/pRK-<i>tatA</i>/pEvol-pBpF /pEXH5<i>tac</i>-H6-A13<i>p</i>Bpa. …”

Supplementary Material for: Decline in Gait Performance Detected by an Electronic Walkway System in 907 Older Adults of the Population-Based KORA-Age Study by Autenrieth C.S. (4134676)

Schematic overview of the experimental setup using the Seraph^® 100 Microbind^® Affinity blood adsorber. by Malin-Theres Seffer (14808772)

Attenuated LDHA or PDK1 expression increases sensitivity of resistant cell lines to Aβ. by Jordan T. Newington (223389)

“…<b>D</b>) Immunoblots of R2 cell lines (clones 71-23 and 72-5) confirming significantly decreased LDHA expression when compared to a control cell line (SCR) (*P<0.01). …”

TDP-43 regulates <i>β-adducin</i> (<i>Add2</i>) transcript stability by Luisa Costessi (13445)

Heparinase treatment ablated daily oscillations in Aβ42 phagocytosis in macrophages. by Gretchen T. Clark (12071965)

“…<p>(A) A violin plot showing the phagocytosis of Aβ42 in the presence of a mixture of heparinases I, II, and III in logged mean fluorescence values plotted against PS and CT. …”

A large proportion of NSCs redivide within 24 to 72 h. by Valerio Lupperger (9745714)

“…(B–E) Example DLS (yellow arrow) for a labeling interval Δt = 9 h. (F) The DLS proportion is high for Δt = 9 h and decreases rapidly with increasing Δt. …”

Data Sheet 1_Pathologic complete response after neoadjuvant therapy for locally advanced rectal cancer in a real-world setting: a population-based study.docx by Lina Cadili (21448478)

“…Aim<p>This study aimed to determine the impact of time from neoadjuvant therapy (NAT) to surgery on the complete pathologic response (pCR) rate in patients with locally advanced rectal cancer. NAT decreases the local recurrence of rectal cancer. Some patients achieve a pCR. …”

Baseline characteristics. by Nattapat Nitinai (17896679)

“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”

Subgroup analyses for the primary outcome. by Nattapat Nitinai (17896679)

“…The montelukast group exhibited a decreased incidence rate of transaminase elevations (0.7% vs 1.4% per day, HR: 0.48, 95%CI 0.25–0.90, P = 0.023).…”